Allogeneic CART progress: platforms, current progress and limitations
Allogenic chimeric antigen receptor T (CAR-T) cells have advantages compared to autologous T cell therapies such as availability cells for production, a suitable HLA-matched donor (if graft-vs-host-disease and rejection effects are to be avoided and also lower risks associated with transduction meth...
Saved in:
| Main Authors: | Ameneh Shokati, Maryam Sanjari-Pour, Mahshid Akhavan Rahnama, Saghar Hoseinzadeh, Mohammad Vaezi, Mohammad Ahmadvand |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1557157/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis
by: Alexander Biederstädt, et al.
Published: (2025-07-01) -
Revolutionizing cancer treatment: engineering mesenchymal stem cell-derived small extracellular vesicles
by: Ameneh Shokati, et al.
Published: (2025-07-01) -
Regulatory T-cells and allogeneic hematopoietic stem cell transplantation
by: O. S. Karavaeva, et al.
Published: (2022-12-01) -
Allogeneic DNT cell therapy synergizes with T cells to promote anti-leukemic activities while suppressing GvHD
by: Jongbok Lee, et al.
Published: (2025-01-01) -
Overcoming Immune Barriers in Allogeneic CAR-NK Therapy: From Multiplex Gene Editing to AI-Driven Precision Design
by: Hyunyoung Kim
Published: (2025-06-01)